- Home
- QLYS vs AXSM Comparison
QLYS vs AXSM Comparison
Compare QLYS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLYS
- AXSM
- Stock Information
- Founded
- QLYS 1999
- AXSM 2012
- Country
- QLYS United States
- AXSM United States
- Employees
- QLYS N/A
- AXSM N/A
- Industry
- QLYS Computer Software: Prepackaged Software
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- QLYS Technology
- AXSM Health Care
- Exchange
- QLYS Nasdaq
- AXSM Nasdaq
- Market Cap
- QLYS 5.1B
- AXSM 4.2B
- IPO Year
- QLYS 2012
- AXSM 2015
- Fundamental
- Price
- QLYS $138.59
- AXSM $88.92
- Analyst Decision
- QLYS Hold
- AXSM Strong Buy
- Analyst Count
- QLYS 18
- AXSM 14
- Target Price
- QLYS $154.19
- AXSM $123.00
- AVG Volume (30 Days)
- QLYS 296.4K
- AXSM 692.6K
- Earning Date
- QLYS 02-05-2025
- AXSM 02-18-2025
- Dividend Yield
- QLYS N/A
- AXSM N/A
- EPS Growth
- QLYS 22.85
- AXSM N/A
- EPS
- QLYS 4.53
- AXSM N/A
- Revenue
- QLYS $592,950,000.00
- AXSM $338,457,000.00
- Revenue This Year
- QLYS $11.24
- AXSM $44.89
- Revenue Next Year
- QLYS $7.62
- AXSM $68.41
- P/E Ratio
- QLYS $30.96
- AXSM N/A
- Revenue Growth
- QLYS 9.66
- AXSM 51.47
- 52 Week Low
- QLYS $119.17
- AXSM $64.11
- 52 Week High
- QLYS $201.03
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- QLYS 45.77
- AXSM 38.33
- Support Level
- QLYS $137.42
- AXSM $75.56
- Resistance Level
- QLYS $142.41
- AXSM $88.59
- Average True Range (ATR)
- QLYS 3.26
- AXSM 4.15
- MACD
- QLYS -0.97
- AXSM -0.83
- Stochastic Oscillator
- QLYS 30.83
- AXSM 47.88
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.